ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatoid Factor"

  • Abstract Number: 0435 • ACR Convergence 2025

    Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study

    Ahmad Alomari1, Reem Elmusa2, Nikita Shah3, Miguel Rodriguez4 and Diala Alawneh5, 1UCF- North Florida hospital, Gainesville, FL, 2UCF/ HCA - North florida hospital, Gainesville, FL, 3UCF/HCA Florida North Florida Hospital, Gainesville, FL, 4SIMED Rheumatology, Gainesville, FL, 5University of Florida, Gainesville, FL

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that manifests as either seropositive or seronegative subtypes. Seropositive RA, characterized by the presence of autoantibodies…
  • Abstract Number: 0430 • ACR Convergence 2025

    Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD

    fatih ŞAhiner1, Mine Nokay2, funda erbasan2, Veli Yazisiz3 and Ender terzioglu2, 1Akdeniz University, Antalya, 2Akdeniz University, Antalya, Turkey, 3Akdeniz University, Faculty of Medicine, Antalya, Turkey

    Background/Purpose: RA-ILD is significant determinants of morbidity and mortality. This study aims to evaluate the demographic and serological characteristics of RA-ILD patients and investigate the…
  • Abstract Number: 2279 • ACR Convergence 2025

    Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial

    Koray Tascilar1, Mikkel Ostergaard2, Verena Schoenau3, Uta Kiltz4, Xenofon Baraliakos4, David Kofler5, Martin Feuchtenberger6, Ulrike Steffen7, Mario Zaiss8, Michael Zaenker9, Reinhard Voll10, Cornelia. Glaser11, Holger Bang12, Eugen feist13, Gerd Burmester14, Kirsten Karberg15, Joachim Strunk16, Juan Cañete17, Esperanza Naredo18, Mária Filková19, Ladislav Šenolt19, Georg Schett20 and Juergen Rech7, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 2Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, 3- Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 5University of Cologne, Cologne, Germany, 6MED | BAYERN OST GmbH, Fachbereich Rheumatologie, Burghausen, Germany, Burghausen, Bayern, Germany, 7Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, Erlangen, Bayern, Germany, 81Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, Erlangen, Bayern, Germany, 9Immanuel Klinikum Bernau , Herzzentrum Brandenburg, Abteilung Innere Medizin, Bernau, Germany, Berlin, Germany, 10University Medical Center Freiburg, Freiburg, Germany, 11Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, Freiburg, Baden-Wurttemberg, Germany, 12Orgentec, Mainz, Germany, 13Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 14Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 15Praxis für Rheumatologie und Innere Medizin, Rheumatologie, Berlin, Germany, Berlin, Germany, 16Krankenhaus Porz am Rhein GmbH, Rheumaklinik, Köln (Porz), Germany, Köln-Porz, Germany, 17Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, 18Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute FJD-UAM, Madrid, Spain, MADRID, Spain, 19Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 20Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany

    Background/Purpose: A 6-month intervention with abatacept in the ARIAA trial (EUDRA-CT 2014–000555–93) significantly retarded the development of RA compared to placebo in ACPA-positive individuals with…
  • Abstract Number: 0155 • ACR Convergence 2025

    Effect Modification of Cigarette Smoking on the Relationship between Post Traumatic Stress Disorder and Rheumatoid Arthritis Risk

    Kelsey Coziahr1, Harlan Sayles1, Tate Johnson1, Joshua Baker2, Punyasha Roul3, Grant Cannon4, Gary Kunkel5, Bryant England1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3UNMC, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Post-traumatic stress disorder (PTSD) is associated with increased systemic inflammation that may increase the risk of developing autoimmune disorders such as rheumatoid arthritis (RA).…
  • Abstract Number: 2274 • ACR Convergence 2025

    Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy

    ELENA GRAU GARCIA1, Iago Alcántara Álvarez2, Jose Ivorra Cortes3, Pablo Muñoz Martinez4, Laura Mas Sanchez5, Alba Maria Torrat Noves6, Daniel Ramos Castro7, Belen Villanueva Manes8, Miguel Simeo Vinaixa4, Andres Perez Hurtado9 and José Andrés Román Ivorra10, 1HUP La Fe, Valencia, Comunidad Valenciana, Spain, 2Hospital Universitari i Politénic La Fe, València, Spain, 3Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, 4Rheumatology Department. HUP La Fe, Valencia, Spain, 5Hospital Universitari i Politecnic La Fe, València, Spain, 6Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, 7Hospital Universitari i Politecnic La Fe, Valencia, Spain, 8Hospital La Fe, València, Spain, 9Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, 10Hospital Universitari i Politècnic La Fe, Valencia, Spain

    Background/Purpose: In patients affected by rheumatoid arthritis (RA), it has been studied a relation between high rheumatoid factor (RF) and a favorable response to anti-TNF…
  • Abstract Number: 0089 • ACR Convergence 2025

    Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis

    Maria-Eugenia Miranda-Carus1, Mariana Gutierrez-Riart2, Beatriz Nieto-Carvalhal3, Laura Nuño2, Alejandro Villalba1, Diana Peiteado1, Irene Monjo Henry1, Marta Novella-Navarro1 and Eugenio de Miguel1, 1Hospital Universitario La Paz, Madrid, Spain, 2Hospital Universitario La Paz, Madrid, 3Hospital Universitario La Paz, Mdrid

    Background/Purpose: Subjects with clinically suspect arthralgia (CSA) are at risk for developing rheumatoid arthritis (RA) and therapeutic interventions may prevent or delay progression. Still, a…
  • Abstract Number: 2268 • ACR Convergence 2025

    Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study

    Clementina López Medina1, Rafaela Ortega-Castro2, Francisco Jose Cepas3, Montserrat Robustillo-Villarino4, Andres Zuniga-Vera4, Ana Martinez-Feito5, Ester Costa-Moya6, Delia Taverner-Torrent6, Luis Sainz Comas7, Cesar Diaz-Torne7, Virginia Ruiz-Esquide8, Cynthia Rojas9, Lourdes Martin-de la Sierra Lopez10, Laura Jimenez-Rodriguez10, David Velasco-Sanchez10, Regina Fará Garcia11, Antonio Juan-Mas12, Marina soledad Moreno Garcia13, Ana Valeria Acosta Alfaro14, Santiago Muñoz15, Maria Martín López16, Raquel Zas17, FRANCISCO JAVIER GODOY NAVARRETE18, Isabel Anon Onate19, Fernando Ortiz-Márquez20, Natalia Mena Vázquez21, Paula Estrada-Alarcón22, Jerusalén Calvo23, Alejandro Escudero Contreras23 and Chamaida Plasencia-Rodríguez24, 1Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 3University of Cordoba, Cordoba, Spain, 4Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, 5Hospital Universitario La Paz, Madrid, Madrid, Spain, 6Hospital Sant Joan Reus, Reus, Spain, 7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 8Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, 9Hospital Clinic, Barcelona, Spain, 10Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 11Hospital Son Llàtzer, Palma, Spain, 12Son Llazter University Hospital, Madrid, Spain, 13Hospital Universitario Miguel Servet, Zaragoza, Spain, 14Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, 15Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, 16Hospital 12 de Octubre, Madrid, Spain, 17Hospital Universitario Doce de Octubre, Madrid, Spain, 18Jaen University Hospital, Spain, Jaen, Spain, 19Hospital Universitario de Jaén, Jaén, Spain, 20Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, 21Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, 22Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, 23IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 24Hospital Universitario La Paz, MADRID, Spain

    Background/Purpose: Rheumatoid factor (RF) is an antibody that contributes to the development of rheumatoid arthritis (RA) and is associated with greater disease severity. Seroconversion of…
  • Abstract Number: 0074 • ACR Convergence 2025

    Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance

    Sophie Hopkin1, Kathryn Malpas1, David Kallenberg1, Jacqueline O'Neill1, Geofrey Odede1, Kerry Tyson1, Sue Cross1, Tatiana SOKOLOVA2, Bernard Lauwerys3, Baran Ufuktepe4, Patrick Durez5, Susanna Bidgood1 and David Humphreys1, 1UCB Pharma, Slough, England, United Kingdom, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 3Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, 4UCB Pharma Istanbul, Turkey, istanbul, Turkey, 5Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

    Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels experience reduced serum drug concentrations and…
  • Abstract Number: 2261 • ACR Convergence 2025

    Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India

    Sryla Punjadath1, Venkatesh Srinivasa Pai1, Prativa Priyadarshani Sethi1, ritu sangwan2, Abhishek Rai3 and Ravi Kant1, 1All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, 2AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, 3AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India

    Background/Purpose: Palindromic Rheumatism (PR) is recognized as a clinical syndrome of intermittent episodes of pain, swelling, and erythema in and around joints, which are severe…
  • Abstract Number: 0073 • ACR Convergence 2025

    HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis

    S. Janna Bashar1, Courtney Myhr1, Adam Titi1, Zihao Zheng1 and Miriam Shelef2, 1University of Wisconsin-Madison, Madison, 2University of Wisconsin-Madison, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross-reactive binding to many antigens containing short motifs, or more private with…
  • Abstract Number: 2248 • ACR Convergence 2025

    Elevated Anti-PAD Autoantibodies in a Singaporean Chinese Rheumatoid Arthritis (RA) Cohort with Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) Positivity: A Case-control Exploratory Study

    Margaret Ma1, Khai Pang Leong2, ee tzun koh2, Preeti Dhanasekaran3, janique peyper4, bermet abylova4, Anselm Mak3 and Peter Cheung1, 1National University Hospital, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4Standard BioTools, Singapore, Singapore

    Background/Purpose: Autoantibody-based biomarkers including ACPA and RF are of established clinical use in rheumatoid arthritis (RA) and are ingrained in international classification criteria. However, other…
  • Abstract Number: 2231 • ACR Convergence 2025

    Inverse Correlation Between Neutrophil Activation and Rheumatoid Factor Concentrations in Rheumatoid Arthritis (RA)

    Anne-Christine Bay-Jensen1, Dovile Sinkeviciute2, Christian Thudium2, shu Sun1, Mathilde Christensen1, Morten Karsdal1, marta Alexdottir1 and Joachim mortensen1, 1Nordic Bioscience A/S, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Neutrophils are crucial in fibro-inflammatory diseases like Crohn's disease (CD) and rheumatoid arthritis (RA), but their biomarkers are better established in CD than in…
  • Abstract Number: 1692 • ACR Convergence 2025

    Rheumatoid factor is associated with increased gut permeability and migration of B cells to the joint via CXCR3 in rheumatoid arthritis

    Ken Yasaka1, Nida Pellett2, Daria Krenitsky1 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical center, Rochester, NY

    Background/Purpose: It has been proposed that the mucosal environment is associated with the pathogenesis of rheumatoid arthritis (RA). In addition to gut dysbiosis, intestinal barrier…
  • Abstract Number: 1366 • ACR Convergence 2025

    Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil

    Rémi Marty1, Baran Ufuktepe2, Nicola Tilt3, Flore Decuypere4, Angela Blake3, Sandeep Kiri3 and Mohammed Soomro3, 1UCB Pharma, Brussels, Belgium, Anderlecht, Belgium, 2UCB Pharma Istanbul, Turkey, istanbul, Turkey, 3UCB Pharma, Slough, United Kingdom, Slough, United Kingdom, 4UCB Pharma Brussels, Belgium, Brussels, Belgium

    Background/Purpose: According to the 2022 EULAR recommendations for the management of rheumatoid arthritis (RA), the presence of rheumatoid factor (RF), particularly at high levels, is…
  • Abstract Number: 1322 • ACR Convergence 2025

    High Rheumatoid Factor Titers and Biologic Persistence in RA: Beyond TNF Inhibitors

    Sara Salas Santamaría1, Marta Chao Moreira2, Manuel Juárez3, Marta Novella-Navarro2, Pilar Nozal2, Ana Martínez2, Carolina Tornero4, Cristina Bohorquez5, Ana Sánchez2, Carmen Cámara2, Eduardo López2, Eugenio de Miguel2 and Chamaida Plasencia-Rodríguez2, 1Hospital Universitario La Paz, Miranda de Ebro, Castilla y Leon, Spain, 2Hospital Universitario La Paz, Madrid, Spain, 3Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 4Hospital La Paz, Madrid, Spain, 5La Paz University Hospital, Alcalá De Henares, Spain

    Background/Purpose: Rheumatoid factor (RF), an autoantibody targeting the Fc portion of IgG, is one of the most studied biomarkers in rheumatoid arthritis (RA). High RF…
  • 1
  • 2
  • 3
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology